希腊某三级学术医院耳念珠菌真菌血症暴发及泛棘白菌素耐药分离株出现,2021至2023年
希腊某三级学术医院耳念珠菌血流感染暴发持续近3年,共89例次,分五波出现,每波间隔6-7个月,均于定植率峰值后3-4个月发生。所有分离株属进化分支I且遗传相关,84%对氟康唑耐药,除一株泛棘白菌素耐药分离株(FKS1S639F突变)外均对两性霉素B和棘白菌素非耐药。2023年耳念珠菌为该院念珠菌血症最常见病因(34%)。
要点
- 耳念珠菌血流感染暴发持续近3年,共89例次,分五波,间隔6-7个月,每波于定植率峰值后3-4个月出现。
- 所有分离株属进化分支I且遗传相关,84%对氟康唑耐药,除一株泛棘白菌素耐药(FKS1S639F突变)外均对两性霉素B和棘白菌素非耐药。
- 2023年耳念珠菌为该院念珠菌血症最常见病因(34%)。
核心结论
- 耳念珠菌真菌血症的加速和长期传播动态强调需要严格的感染控制措施。
- 抗真菌药物管理有助于遏制棘白菌素耐药分离株的选择。
研究设计与样本
- 研究在希腊某三级学术医院进行,描述2021至2023年耳念珠菌真菌血症暴发,共89例次。
主要发现
- 89例次耳念珠菌血流感染分五波出现,每波间隔6-7个月,均于定植率峰值后3-4个月发生。
- 所有分离株属进化分支I且遗传相关。
- 84%的分离株对氟康唑耐药,所有分离株对两性霉素B和棘白菌素非耐药,除外一株泛棘白菌素耐药分离株(FKS1S639F突变)。
- 该泛棘白菌素耐药分离株来自一名接受阿尼芬净经验性治疗的患者。
- 2023年耳念珠菌为该院念珠菌血症最常见病因(34%)。
临床怎么用
- 原文强调需要严格的感染控制措施,并认为抗真菌药物管理有助于遏制棘白菌素耐药分离株的选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
After the start of the COVID-19 pandemic, a rapid rise in reported numbers and wide geographic spread of Candida auris-related invasive infections has been observed globally. However, the contemporary epidemiology of C. auris fungaemias in Greece remains unknown. An outbreak of C. auris bloodstream infections has been ongoing for almost 3 years in a Greek tertiary care academic hospital, with 89 C. auris-driven episodes appearing in five waves every 6-7 months following peaks in colonisation rates by 3-4 months. All isolates clustered in clade I and were genetically related, 84% were fluconazole-resistant and all were non-resistant to amphotericin B and echinocandins, except one pan-echinocandin-resistant isolate (FKS1S639F mutant) recovered from a patient on empiric therapy with anidulafungin. Notably, C. auris was in 2023 the most prevalent (34%) cause of candidaemia in our hospital. The accelerated and long-term transmission dynamics of C. auris fungaemia underscore the need for rigorous infection control measures, while antifungal stewardship is warranted to contain the selection of echinocandin-resistant isolates.
引用
- Meletiadis J, Siopi M, Spruijtenburg B, et al. Candida auris fungaemia outbreak in a tertiary care academic hospital and emergence of a pan-echinocandin resistant isolate, Greece, 2021 to 2023. Euro Surveill. 2024. PMID: 39512169. doi:10.2807/1560-7917.ES.2024.29.45.2400128
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。